Literature DB >> 23765537

Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Erin R Rudzinski1, Lisa A Teot, James R Anderson, Julie Moore, Julia A Bridge, Frederic G Barr, Julie M Gastier-Foster, Stephen X Skapek, Douglas S Hawkins, David M Parham.   

Abstract

OBJECTIVES: To examine whether the frequency of fusion-negative alveolar rhabdomyosarcoma (ARMSn) increased coincident with changes in the definition of alveolar histology.
METHODS: We re-reviewed alveolar rhabdomyosarcoma (ARMS) in the Children's Oncology Group study D9803, comparing histopathology with fusion status.
RESULTS: Our review of 255 original ARMS cases (compared with a control group of 38 embryonal rhabdomyosarcomas [ERMS] cases) revealed that many had an ARMS-like densely cellular pattern with cytologic features and myogenin expression more typical of ERMS. Following re-review, 84 (33%) cases of original ARMS were rediagnosed as ERMS. All reclassified ERMS, including dense ERMS, were fusion negative, whereas 82% of confirmed ARMS cases were fusion positive. Total ARMS diagnoses returned to historic rates of 25% to 30% of all rhabdomyosarcomas, and ARMSn decreased from 37% to 18% of ARMS cases. The outcome of reclassified ERMS was similar to confirmed ERMS.
CONCLUSIONS: To address the role of fusion status in risk stratification, pathologists should include both a histologic diagnosis and an evaluation of fusion status for all new ARMS diagnoses.

Entities:  

Keywords:  Alveolar rhabdomyosarcoma; Embryonal rhabdomyosarcoma; Histologic classification; Myogenin; Rhabdomyosarcoma

Mesh:

Substances:

Year:  2013        PMID: 23765537      PMCID: PMC4624292          DOI: 10.1309/AJCPA1WN7ARPCMKQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  22 in total

1.  Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.

Authors:  Frederic G Barr; Stephen J Qualman; Michele H Macris; Natalya Melnyk; Elizabeth R Lawlor; Donna M Strzelecki; Timothy J Triche; Julia A Bridge; Poul H B Sorensen
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

2.  Epithelioid rhabdomyosarcoma: clinicopathologic analysis of 16 cases of a morphologically distinct variant of rhabdomyosarcoma.

Authors:  Vickie Y Jo; Adrián Mariño-Enríquez; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

3.  Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass.

Authors:  P Dias; B Chen; B Dilday; H Palmer; H Hosoi; S Singh; C Wu; X Li; J Thompson; D Parham; S Qualman; P Houghton
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

Review 4.  Molecular pathogenesis of rhabdomyosarcoma.

Authors:  Shujuan J Xia; Joseph G Pressey; Frederic G Barr
Journal:  Cancer Biol Ther       Date:  2002 Mar-Apr       Impact factor: 4.742

5.  PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.

Authors:  Stephen X Skapek; James Anderson; Frederic G Barr; Julia A Bridge; Julie M Gastier-Foster; David M Parham; Erin R Rudzinski; Timothy Triche; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2013-03-22       Impact factor: 3.167

6.  An English Translation of Joseph Luc Riopelle, MD, (Hôtel-Dieu of Montréal), and Jean Paul Thériault (Hôpital Général of Verdun, Québec, Canada): Sur une forme méconnue de sarcome des parties molles: le rhabdomyosarcome alvéolaire (concerning an unrecognized form of sarcoma of the soft tissues: alveolar rhabdomyosarcoma). annales d'anatomie pathologique 1956;1:88-111.

Authors:  R Beverly Raney; Odile Oberlin; David M Parham
Journal:  Pediatr Dev Pathol       Date:  2012 Sep-Oct

7.  Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study.

Authors:  W A Newton; E A Gehan; B L Webber; H B Marsden; A J van Unnik; A B Hamoudi; M G Tsokos; H Shimada; D Harms; D Schmidt
Journal:  Cancer       Date:  1995-09-15       Impact factor: 6.860

8.  Spindle cell variants of embryonal rhabdomyosarcoma in the paratesticular region. A report of the Intergroup Rhabdomyosarcoma Study.

Authors:  I Leuschner; W A Newton; D Schmidt; N Sachs; L Asmar; A Hamoudi; D Harms; H M Maurer
Journal:  Am J Surg Pathol       Date:  1993-03       Impact factor: 6.394

9.  Rhabdomyosarcoma. A new classification scheme related to prognosis.

Authors:  M Tsokos; B L Webber; D M Parham; R A Wesley; A Miser; J S Miser; E Etcubanas; T Kinsella; J Grayson; E Glatstein
Journal:  Arch Pathol Lab Med       Date:  1992-08       Impact factor: 5.534

10.  Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.

Authors:  Andrew L Folpe; Jesse K McKenney; Julia A Bridge; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2002-09       Impact factor: 6.394

View more
  28 in total

1.  Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.

Authors:  Michael A Arnold; James R Anderson; Julie M Gastier-Foster; Frederic G Barr; Stephen X Skapek; Douglas S Hawkins; R Beverly Raney; David M Parham; Lisa A Teot; Erin R Rudzinski; David O Walterhouse
Journal:  Pediatr Blood Cancer       Date:  2016-01-12       Impact factor: 3.167

2.  Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Authors:  Douglas S Hawkins; Yueh-Yun Chi; James R Anderson; Jing Tian; Carola A S Arndt; Lisa Bomgaars; Sarah S Donaldson; Andrea Hayes-Jordan; Leo Mascarenhas; Mary Beth McCarville; Jeannine S McCune; Geoff McCowage; Lynn Million; Carol D Morris; David M Parham; David A Rodeberg; Erin R Rudzinski; Margarett Shnorhavorian; Sheri L Spunt; Stephen X Skapek; Lisa A Teot; Suzanne Wolden; Torunn I Yock; William H Meyer
Journal:  J Clin Oncol       Date:  2018-08-09       Impact factor: 44.544

3.  Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.

Authors:  Erin R Rudzinski; James R Anderson; Elizabeth R Lyden; Julia A Bridge; Frederic G Barr; Julie M Gastier-Foster; Karen Bachmeyer; Stephen X Skapek; Douglas S Hawkins; Lisa A Teot; David M Parham
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

4.  Potential Value of YAP Staining in Rhabdomyosarcoma.

Authors:  Atif A Ahmed; Sultan S Habeebu; Ashley K Sherman; Shui Q Ye; Nicole Wood; Katherine M Chastain; Maria G Tsokos
Journal:  J Histochem Cytochem       Date:  2018-03-29       Impact factor: 2.479

5.  Paratesticular alveolar rhabdomyosarcomas do not harbor typical translocations: a distinct entity with favorable prognosis?

Authors:  Tobias M Dantonello; Christian Vokuhl; Monika Scheer; Monika Sparber-Sauer; Sabine Stegmaier; Guido Seitz; Heike Scheithauer; Jörg Faber; Iris Veit-Friedrich; Peter Kaatsch; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak
Journal:  Virchows Arch       Date:  2018-02-21       Impact factor: 4.064

6.  Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma.

Authors:  Shih-Chiang Huang; Rita Alaggio; Yun-Shao Sung; Chun-Liang Chen; Lei Zhang; Yu-Chien Kao; Narasimhan P Agaram; Leonard H Wexler; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-07       Impact factor: 6.394

7.  Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:  Erin R Rudzinski; James R Anderson; Yueh-Yun Chi; Julie M Gastier-Foster; Caroline Astbury; Frederic G Barr; Stephen X Skapek; Douglas S Hawkins; Brenda J Weigel; Alberto Pappo; William H Meyer; Michael A Arnold; Lisa A Teot; David M Parham
Journal:  Pediatr Blood Cancer       Date:  2017-05-18       Impact factor: 3.167

Review 8.  What is new in the biology and treatment of pediatric rhabdomyosarcoma?

Authors:  Douglas S Hawkins; Abha A Gupta; Erin R Rudzinski
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

9.  Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups.

Authors:  David O Walterhouse; Donald A Barkauskas; David Hall; Andrea Ferrari; Gian Luca De Salvo; Ewa Koscielniak; Michael C G Stevens; Hélène Martelli; Guido Seitz; David A Rodeberg; Margarett Shnorhavorian; Roshni Dasgupta; John C Breneman; James R Anderson; Christophe Bergeron; Gianni Bisogno; William H Meyer; Douglas S Hawkins; Veronique Minard-Colin
Journal:  J Clin Oncol       Date:  2018-10-23       Impact factor: 44.544

10.  Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  Abby R Rosenberg; James R Anderson; Elizabeth Lyden; David A Rodeberg; Suzanne L Wolden; Simon C Kao; David M Parham; Carola Arndt; Douglas S Hawkins
Journal:  Eur J Cancer       Date:  2013-12-18       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.